two women smiling and embracing each other

Changing the view of cancer

Elephas is committed to helping pharmaceutical and biotechnology researchers accelerate immunotherapy drug development with a breakthrough approach for assessing response to investigational agents.

Powered by our Cybrid™ platform, our technology suite is the only solution based on live tumor fragments (LTF)™ with the native tumor architecture and immune cells intact.

With Cybrid™ we can generate an array of outputs, including secretome profiling, cellular markers, transcriptome analysis, and advanced 3D imaging using multiphoton microscopy and optical coherence tomography.*

* For Research Use Only. Not for use in diagnostic procedures.

RAPID RESULTS, ACTIONABLE DATA SETS

Within two weeks of the study start date, we can offer data and visualization of the impact of your agent on a tumor and its immune cells.* This rapid turnaround provides insights and understanding of the agent’s potential impact on patients. Results are delivered through seamless and frictionless exports of full data sets through our secure cloud-based portal, CybridView™.

*<20 patient samples, time from receipt of test article

COLLABORATION AND COOPERATION

Elephas will support your studies from initial design through final data readouts. Along with the wealth of data our technology suite will provide, your team will have direct access to our expert cancer biologists and analysts. This unique connection is vital in setting our partners ahead of competitors and ensuring the highest probability of success for assets.

THE POWER TO ACCELERATE EVERY STEP OF DISCOVERY AND DEVELOPMENT

Applications across the entire continuum will bring change to the Oncology landscape

BASIC RESEARCH

Explore MOA in Syngeneic and/or PDX models

DRUG DISCOVERY

Interrogate with multiple candidates, controls, and methods

PRECLINICAL

Candidate selection process

CLINICAL TRIALS

De-risk clinical trials
& shape combination therapy

LABEL EXPANSION

Screen across multiple tumor types for label expansion